If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
775.00    0.00 (0.00%)
Bid:
731.00
Ask:
820.00
Spread: 89.00 (12.175%)
Market Cap: £52.70m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Director/PDMR Shareholding

12 Feb 2018 07:00

RNS Number : 5133E
Hemogenyx Pharmaceuticals PLC
12 February 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Director / PDMR Shareholding

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN GB00BYX3WZ24

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

2.1p

200,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

9 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDDDGBGIC
Date   Source Headline
8th Jun 20187:00 amRNSInvestor presentation
5th Jun 20186:05 pmRNSPosting of Annual Report & Notice of AGM
14th May 20187:00 amRNSDevelopment Agreement
8th May 20187:00 amRNSResearch Collaboration with Rockefeller University
30th Apr 20184:23 pmRNSFinal Results
11th Apr 20185:15 pmRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSDirectorate Change
14th Mar 201811:05 amRNSSecond Price Monitoring Extn
14th Mar 201811:00 amRNSPrice Monitoring Extension
13th Mar 20187:00 amRNSCollaboration with major US biotechnology company
6th Mar 20187:00 amRNSAdvisory Board Appointment
1st Mar 20187:00 amRNSAlign Research Initiation of Coverage
27th Feb 20184:40 pmRNSSecond Price Monitoring Extn
27th Feb 20184:35 pmRNSPrice Monitoring Extension
26th Feb 20182:17 pmRNSStmnt re Share Price Movement
12th Feb 20187:00 amRNSDirector/PDMR Shareholding
7th Feb 20187:00 amRNSDirector/PDMR Shareholding
11th Jan 20187:00 amRNSHemogenyx Welcomes N.Y. Lt. Governor to its Labs
7th Dec 201712:16 pmRNSResult of AGM
7th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSUniversity of Oxford Collaboration
15th Nov 20177:00 amRNSDirectorate Change
14th Nov 20177:00 amRNSNotice of AGM
13th Nov 20174:40 pmRNSSecond Price Monitoring Extn
13th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20172:05 pmRNSSecond Price Monitoring Extn
13th Nov 20172:00 pmRNSPrice Monitoring Extension
13th Nov 201711:05 amRNSSecond Price Monitoring Extn
13th Nov 201711:00 amRNSPrice Monitoring Extension
13th Nov 20179:05 amRNSSecond Price Monitoring Extn
13th Nov 20179:00 amRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSStatement re Press Comment
30th Oct 20177:00 amRNSLakePharma appointed for lead product development
11th Oct 20177:00 amRNSDirector/PDMR Shareholding
10th Oct 20177:00 amRNSDirector/PDMR Shareholding
5th Oct 20178:01 amRNSCornell University update
5th Oct 20178:00 amRNSAdmission & First Day of Dealings
4th Oct 201711:16 amRNSResult of General Meeting
26th Sep 20177:00 amRNSInvestor presentations
25th Sep 20177:00 amRNSHalf-year Report
11th Sep 20177:00 amRNSProposed acquisition and Placing & Subscription
13th Apr 20173:30 pmRNSFinal Results
30th Sep 20162:00 pmRNSProposed acquisition of Lime Holdings Limited
5th Aug 20167:00 amRNSInterim Report for the period ended 30 June 2016
29th Jun 20167:00 amRNSResults of Annual General Meeting
1st Jun 20169:43 amRNSPosting of Annual Report & Accounts
28th Apr 20167:00 amRNSFinal Results for period ended 31 December 2015
18th Feb 201610:33 amRNSChange of Accounting Reference Date
30th Dec 20157:00 amRNSStatement re possible acquisition
23rd Dec 201512:48 pmRNSSuspension of trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.